Evidence map›Paper›PMID 21732159›Full record

ArticleAAPS PharmSciTech2011

Platelet lysate mucohadesive formulation to treat oral mucositis in graft versus host disease patients: a new therapeutic approach.

Claudia Del Fante, Cesare Perotti, Maria Cristina Bonferoni, Silvia Rossi, Giuseppina Sandri, Franca Ferrari, Luigia Scudeller, Carla Marcella Caramella

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in AAPS PharmSciTech, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04487691 (Autologous Nebulized Platelet Lysate for Post COVID-19 Syndrome), which is not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04487691 naterminatednot on this mapstarted 2020, after this paper: background citation

Autologous Nebulized Platelet Lysate for Post COVID-19 Syndrome

TypeinterventionalSponsorRegenexx, LLCRan2020 to 2021Enrolled1ConditionsCovid19ArmsNebulized Platelet Lysate, Nebulized Sterile Saline
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 48 citations in OpenAlex.

  1. Platelet gel in cutaneous radiation dermatitis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013
    Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Angiogenic factors and inflammation in steroid-refractory acute graft-vs-host disease.Translational research : the journal of laboratory and clinical medicine · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Claudia Del FanteImmunohaematology and Transfusion Service, Apheresis And Cell Therapy Unit, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
Cesare Perotti
Maria Cristina Bonferoni
Silvia Rossi
Giuseppina Sandri
Franca Ferrari
Luigia Scudeller
Carla Marcella Caramella
University of Pavia · ITPoliclinico San Matteo Fondazione · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optimal treatment of oral mucositis (OM) due to graft versus host disease (GvHD) is currently not available. Platelet-derived growth factors (PDGFs) have high capability for tissue healing and may play a role in repairing the mucosal barrier. The aim of the present work was to develop a mucoadhesive formulation to administer platelet lysate to oral cavity prolonging contact time of platelet lysate with oral mucosa. The mucoadhesive formulation was characterized for in vitro properties (PDGF-AB concentration, mucoadhesive properties, cytotoxicity, fibroblast proliferation, wound healing). Moreover, a preliminary clinical study on seven GvHD patients with OM refractory to other therapies was conducted, to evaluate feasibility, safety, and efficacy. GVPL (mucoadhesive gel vehicle mixed with platelet lysate)showed good mucoadhesive properties; additionally, it was characterized by good biocompatibility in vitro on fibroblasts and it was able to enhance fibroblast proliferation and wound healing, maintaining the efficacy for up to 14 days following storage at 2-8°C. In vivo, clinical response was good-to-complete in five, fair in one, none in the remaining one. The in vitro results indicate that GVPL has optimal mucoadhesive and healing enhancer properties, maintained over time (up to 14 days); preliminary clinical results suggest that oral application of platelet lysate-loaded mucoadhesive formulation is feasible, safe, well tolerated, and effective. A larger controlled randomized study is needed.

Indexed as

AcrylatesAdministration, BuccalAdolescentAdultBlood PlateletsCell ExtractsCell ProliferationCells, CulturedFibroblastsGraft vs Host DiseaseHumansMiddle AgedMouth MucosaPlatelet-Derived Growth FactorStomatitisTissue AdhesivesAcrylatescarbopol 974P NFCell ExtractsPlatelet-Derived Growth Factorplatelet-derived growth factor ABTissue Adhesives

Identifiers

PMID21732159
PMCPMC3167256
OpenAlexW1973450143

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.